Nanology Labs develops a first-in-class TUMOR MOULATING THERAPEUTIC PLATROM TECHNOGY, enabling tumor environment modification to boost anti-tumor immunity and improve chemo and radiation therapies. Nanology Labs is addressing an imperative unmet clinical need with the total and addressable market values of $97B and $36B.
Nanology Labs’ lead asset, Manganescan, is nanoparticle-based tumor modulating agent that can decrease the immunosuppressive and treatment-resistant factors in the tumor via oxygenating tumors and killing cancer cells in combination with other therapeutic modalities, particularly radiation therapy. The combination therapy of Manganescan with Radiation therapy has pre-clinically confirmed the significant improvement in life expectancy and more strikingly, 40% curative result. The product is safer and more efficacious than the commercially available options and enables broad applicability across various tumor types.
Nanology Labs is seeking $6.5M Series A raise to accomplish late-IND enabling and Phase 1/2a clinical studies.